에리스로포이에틴 제제 시장 : 세계 산업 분석, 규모, 점유율, 수량, 성장, 동향 및 예측(2024-2034년)
Erythropoietin Drugs Market (Drug Class: Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, and Others; and Drug Type: Biologics and Biosimilar) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast, 2024-2034
상품코드:1487595
리서치사:Transparency Market Research
발행일:2024년 04월
페이지 정보:영문 237 Pages
라이선스 & 가격 (부가세 별도)
한글목차
에리스로포이에틴 제제 시장- 조사 범위
TMR의 조사 보고서 "에리스로포이에틴 제제 세계 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고 2024년을 기준 연도로, 2034년을 예측 연도로 삼았다, 2018년부터 2034년까지 세계 에리스로포이에틴 제제 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 에리스로포이에틴 제제 시장의 복합 연간 성장률(CAGR%)도 제공합니다.
이 보고서는 광범위한 1차 연구, KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체와의 인터뷰, 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 에리스로포이에틴 제제 시장을 이해하기 위한 2차 연구를 통해 작성되었습니다.
시장 현황
2023년 시장 규모
94억 달러
2034년 시장 가치
143억 달러
CAGR
3.8%
이 보고서는 세계 에리스로포이에틴 제제 시장의 경쟁 환경에 대해 자세히 연구하고 있습니다. 세계 에리스로포이에틴 제제 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에서 다루는 세계 에리스로포이에틴 제제 시장의 기업 속성입니다.
목차
제1장 서문
제2장 조사의 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
서론
시장 개요
시장 역학
세계 시장 분석과 예측, 2020년-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 M&A
COVID-19 팬데믹의 업계에 대한 영향
제6장 세계 시장 분석과 예측 : 약제 클래스별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 약제 클래스별, 2020년-2034년
Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
기타
시장의 매력 : 약제 클래스별
제7장 세계 시장 분석과 예측 : 약제 유형별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 약제 유형별, 2020년-2034년
생물제제
바이오시밀러
시장의 매력 : 약제 유형별
제8장 세계 시장 분석과 예측 : 의약품 용도별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 의약품 용도별, 2020년-2034년
암
신장질환
혈액
신경
기타
시장의 매력 : 의약품 용도별
제9장 세계 시장 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 유통 채널별, 2020년-2034년
병원 약국
소매 약국
온라인 약국
시장의 매력 : 유통 채널별
제10장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020년-2034년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제11장 북미 시장 분석과 예측
제12장 유럽 시장 분석과 예측
제13장 아시아태평양 시장 분석과 예측
제14장 라틴아메리카 시장 분석과 예측
제15장 중동 및 아프리카 시장 분석과 예측
제16장 경쟁 구도
시장 경쟁 매트릭스(기업 Tier별, 기업 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Amgen, Inc.
Novartis AG
F. Hoffmann-La Roche Ltd.
GCK
Merck & Co., Inc.
Johnson & Johnson
Wockhardt Ltd.
Pfizer, Inc.
Biocon Ltd.
Teva Pharmaceutical Industries Ltd.
LSH
영문 목차
영문목차
Erythropoietin Drugs Market - Scope of Report
TMR's report on the global erythropoietin drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global erythropoietin drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global erythropoietin drugs market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the erythropoietin drugs market.
Market Snapshot
Market Value in 2023
US$ 9.4 Bn
Market Value in 2034
US$ 14.3 Bn
CAGR
3.8%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global erythropoietin drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global erythropoietin drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global erythropoietin drugs market.
The report delves into the competitive landscape of the global erythropoietin drugs market. Key players operating in the global erythropoietin drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global erythropoietin drugs market profiled in this report.
Key Questions Answered in Global erythropoietin drugs Market Report:
What is the sales/revenue generated by erythropoietin drugs across all regions during the forecast period?
What are the opportunities in the global erythropoietin drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Erythropoietin Drugs Market - Research Objectives and Research Approach
The comprehensive report on the global erythropoietin drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global erythropoietin drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global erythropoietin drugs market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Erythropoietin Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Erythropoietin Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Erythropoietin Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Epoetin Alfa
6.3.2. Epoetin Beta
6.3.3. Darbepoetin Alfa
6.3.4. Others
6.4. Market Attractiveness, by Drug Class
7. Global Erythropoietin Drugs Market Analysis and Forecast, by Drug Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Type, 2020-2034
7.3.1. Biologics
7.3.2. Biosimilar
7.4. Market Attractiveness, by Drug Type
8. Global Erythropoietin Drugs Market Analysis and Forecast, by Drug Application
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Drug Application, 2020-2034
8.3.1. Cancer
8.3.2. Renal Disease
8.3.3. Hematology
8.3.4. Neurology
8.3.5. Others
8.4. Market Attractiveness, by Drug Application
9. Global Erythropoietin Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Attractiveness, by Distribution Channel
10. Global Erythropoietin Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Erythropoietin Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2020-2034
11.2.1. Epoetin Alfa
11.2.2. Epoetin Beta
11.2.3. Darbepoetin Alfa
11.2.4. Others
11.3. Market Attractiveness, by Drug Class
11.4. Market Value Forecast, by Drug Type, 2020-2034
11.4.1. Biologics
11.4.2. Biosimilar
11.5. Market Attractiveness, by Drug Type
11.6. Market Value Forecast, by Drug Application, 2020-2034
11.6.1. Cancer
11.6.2. Renal Disease
11.6.3. Hematology
11.6.4. Neurology
11.6.5. Others
11.7. Market Attractiveness, by Drug Application
11.8. Market Value Forecast, by Distribution Channel, 2020-2034
11.8.1. Hospital Pharmacy
11.8.2. Retail Pharmacy
11.8.3. Online Pharmacy
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Drug Class
11.11.2. By Drug Type
11.11.3. By Drug Application
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Erythropoietin Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2020-2034
12.2.1. Epoetin Alfa
12.2.2. Epoetin Beta
12.2.3. Darbepoetin Alfa
12.2.4. Others
12.3. Market Attractiveness, by Drug Class
12.4. Market Value Forecast, by Drug Type, 2020-2034
12.4.1. Biologics
12.4.2. Biosimilar
12.5. Market Attractiveness, by Drug Type
12.6. Market Value Forecast, by Drug Application, 2020-2034
12.6.1. Cancer
12.6.2. Renal Disease
12.6.3. Hematology
12.6.4. Neurology
12.6.5. Others
12.7. Market Attractiveness, by Drug Application
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacy
12.8.2. Retail Pharmacy
12.8.3. Online Pharmacy
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Drug Class
12.11.2. By Drug Type
12.11.3. By Drug Application
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Erythropoietin Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2020-2034
13.2.1. Epoetin Alfa
13.2.2. Epoetin Beta
13.2.3. Darbepoetin Alfa
13.2.4. Others
13.3. Market Attractiveness, by Drug Class
13.4. Market Value Forecast, by Drug Type, 2020-2034
13.4.1. Biologics
13.4.2. Biosimilar
13.5. Market Attractiveness, by Drug Type
13.6. Market Value Forecast, by Drug Application, 2020-2034
13.6.1. Cancer
13.6.2. Renal Disease
13.6.3. Hematology
13.6.4. Neurology
13.6.5. Others
13.7. Market Attractiveness, by Drug Application
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacy
13.8.2. Retail Pharmacy
13.8.3. Online Pharmacy
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Drug Class
13.11.2. By Drug Type
13.11.3. By Drug Application
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Erythropoietin Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2020-2034
14.2.1. Epoetin Alfa
14.2.2. Epoetin Beta
14.2.3. Darbepoetin Alfa
14.2.4. Others
14.3. Market Attractiveness, by Drug Class
14.4. Market Value Forecast, by Drug Type, 2020-2034
14.4.1. Biologics
14.4.2. Biosimilar
14.5. Market Attractiveness, by Drug Type
14.6. Market Value Forecast, by Drug Application, 2020-2034
14.6.1. Cancer
14.6.2. Renal Disease
14.6.3. Hematology
14.6.4. Neurology
14.6.5. Others
14.7. Market Attractiveness, by Drug Application
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacy
14.8.2. Retail Pharmacy
14.8.3. Online Pharmacy
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Drug Class
14.11.2. By Drug Type
14.11.3. By Drug Application
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Erythropoietin Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2020-2034
15.2.1. Epoetin Alfa
15.2.2. Epoetin Beta
15.2.3. Darbepoetin Alfa
15.2.4. Others
15.3. Market Attractiveness, by Drug Class
15.4. Market Value Forecast, by Drug Type, 2020-2034
15.4.1. Biologics
15.4.2. Biosimilar
15.5. Market Attractiveness, by Drug Type
15.6. Market Value Forecast, by Drug Application, 2020-2034
15.6.1. Cancer
15.6.2. Renal Disease
15.6.3. Hematology
15.6.4. Neurology
15.6.5. Others
15.7. Market Attractiveness, by Drug Application
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacy
15.8.2. Retail Pharmacy
15.8.3. Online Pharmacy
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Drug Class
15.11.2. By Drug Type
15.11.3. By Drug Application
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Amgen, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Novartis AG
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. GCK
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Merck & Co., Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Johnson & Johnson
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Wockhardt Ltd.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Pfizer, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Biocon Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Teva Pharmaceutical Industries Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
